Showing 1821-1830 of 5063 results for "".
- RXI Completes Enrollment of Phase 2 Study of Samcyprone for Cutaneous Wartshttps://practicaldermatology.com/news/rxi-completes-enrollment-of-phase-2-study-of-samcyprone-for-cutaneous-warts/2458067/RXi Pharmaceuticals Corporation completed enrollment in its Phase 2 clinical trial, RXI-SCP-1502, with Samcyprone™for the clearance of cutaneous warts. Samcyprone™ is a proprietary topical formulation of the small molecule diphenylcyclopr
- Skin Color Affects Skin Sensitivity to Heat and Mechanical Stimulihttps://practicaldermatology.com/news/skin-color-affects-skin-sensitivity-to-heat-and-mechanical-stimuli/2458069/Researchers at the Bluestone Center for Clinical Research at the New York University College of Dentistry (NYU Dentistry) have identified a novel molecular mechanism which explains why dark-skinned and light-skinned people respond differently to heat and mechanical stimulation. In a study
- Psoriasis Severity Linked to Increased Risk of Deathhttps://practicaldermatology.com/news/psoriasis-severity-linked-to-increased-risk-of-death/2458074/The more surface area of the body covered by psoriasis, the greater the risk of death, according to a new analysis by researchers at the Perelman School of Medicine at the University of Pennsylvania. In fact, patients with psoriasis on 10 perce
- Protea Expands Clinical Study for New Melanoma Testhttps://practicaldermatology.com/news/protea-expands-clinical-study-for-new-melanoma-test/2458083/Protea Biosciences Group, Inc. is expanding its clinical research study for their new molecular imaging test for the differential diagnosis of malignant melanoma. The study has now surpassed 250 patient samples, the company reports. The propr
- PuraCap Pharmaceuticals Introduces EpiCeram Quad Packhttps://practicaldermatology.com/news/puracap-pharmaceuticals-introduces-epiceram-quad-pack/2458088/PuraCap® Pharmaceutical is introducing the EpiCeram® Controlled Release Skin Barrier Emulsion Quad Pack, which contains four 100-gram airless pumps. EpiCeram® is a US Food and Drug Administration-approved topical prescription e
- Review Study Suggests Vitamin B3 May Prevent Melanomahttps://practicaldermatology.com/news/review-study-suggests-vitamin-b3-may-prevent-melanoma/2458093/Nicotinamide (Vitamin B3) may help stave off melanoma in high-risk individuals, a new review study suggests. “Nicotinamide has been shown in a clinical trial—called ONTRAC—to reduce the incidence of non-melanoma skin cancer in high-risk individuals and it would be worthw
- Modernizing Medicine To Add More Than 800 Jobs in Expansionhttps://practicaldermatology.com/news/modernizing-medicine-to-add-more-than-800-jobs-in-expansion/2458101/Modernizing Medicine will expand operations and add a total of 838 jobs by 2022. The expansion, to be implemented in the historic Boca Raton Innovation Center (BRIC) in Palm Beach County will result in a capital investment of more than $15 million in the Boca Raton community.
- LEO Pharma Receives EU Marketing Authorization for Kyntheum to Treat Plaque Psoriasishttps://practicaldermatology.com/news/leo-pharma-receives-eu-marketing-authorization-for-kyntheumfor-the-treatment-of-plaque-psoriasis/2458114/The European Commission has granted marketing authorisation for LEO Pharma's Kyntheum (brodalumab), a new biologic for the treatment of moderate-to-severe plaque psoriasis in adults within the European Union who are candidates for systemic therapy. Kyntheum selectively targets the IL-17 recep
- Syneron Candela Completes Transaction with Funds Advised by Apax Partners; Becomes a Private Companyhttps://practicaldermatology.com/news/syneron-candela-completes-transaction-with-funds-advised-by-apax-partners-becomes-a-private-company/2458121/Syneron Medical Ltd. announced the successful completion of its acquisition by an affiliate of funds advised by Apax Partners for $11.00 per share in cash in a transaction valued at approximately $400 million. The transacti
- Allergan CEO: Consensus Needed on Medical Aesthetic Treatment in Minorshttps://practicaldermatology.com/news/allergan-ceo-consensus-needed-on-medical-aesthetic-treatment-in-minors/2458125/Allergan Chairman & CEO Brent Saunders, the father of two high school-aged girls, is speaking up and out about the risks associated with offering medical aesthetic treatments to minors. In a new blog post, he writes “we must remember that anyone under the age of 18 is still matu